Cargando…

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression

Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pantarotto, Marcos, Barata, Rita, Coelho, Ricardo, Sousa, Virginia, Carvalheiro, Catarina, Rolim, Ines, Garrido, Patricia, GIl, Nuno, Duarte-Ramos, Filipa, Tonin, Fernanda S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364060/ https://www.ncbi.nlm.nih.gov/pubmed/35967142 http://dx.doi.org/10.7759/cureus.26729

Ejemplares similares

Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2023)

Case report: Using DNA short tandem repeats to confirm nongestational origin of pulmonary choriocarcinoma
por: da Silva, Filipa Ferreira, et al.
Publicado: (2022)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
por: Sanderson, Emma, et al.
Publicado: (2020)

Fever and Cervical Lymphadenopathy in a Young Female; Thinking Beyond Tuberculosis
por: Khadanga, Sagar, et al.
Publicado: (2014)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
por: Mayadev, Jyoti, et al.
Publicado: (2020)

Cervical Lymphadenopathy in a Nonagenarian Woman: What to Think?
por: Chaves, Vanessa Meireles, et al.
Publicado: (2019)

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
por: Park, S., et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2020)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
por: Denault, Marie-Hélène, et al.
Publicado: (2023)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis
por: Barata, Fernando, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post‐operative recurrent pulmonary pleomorphic carcinoma
por: Shimamura, So, et al.
Publicado: (2021)

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma
por: Mikami, Erika, et al.
Publicado: (2023)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
por: Joshi, Monika, et al.
Publicado: (2023)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
por: Matsuura, Shun, et al.
Publicado: (2020)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
por: Ismaili, Nabil, et al.
Publicado: (2009)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2021)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
por: Spigel, David R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a5gqv1gpu0lej8asaot3n4ceei